BioLineRx (BLRX) Projected to Post Earnings on Tuesday

BioLineRx (NASDAQ:BLRX) is expected to be announcing its earnings results before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($4.20) per share and revenue of $7.72 million for the quarter.

BioLineRx Stock Performance

Shares of NASDAQ:BLRX opened at $3.22 on Tuesday. BioLineRx has a 1 year low of $2.88 and a 1 year high of $56.00. The stock has a market capitalization of $10.72 million, a price-to-earnings ratio of -0.37 and a beta of 1.39. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37. The company’s 50 day simple moving average is $3.89 and its 200 day simple moving average is $12.31.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. StockNews.com started coverage on BioLineRx in a research note on Tuesday, February 4th. They issued a “hold” rating on the stock. HC Wainwright decreased their target price on BioLineRx from $840.00 to $360.00 and set a “buy” rating on the stock in a research report on Monday, November 25th.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.